黛柏湿疹膏联合封包疗法治疗慢性湿疹脾虚血燥证的临床观察

Clinical Observation of Daibai Eczema Ointment Combined with Packet Therapy in the Treatment of Chronic Eczema Complicated with Spleen Deficiency and Blood Dryness Syndrome

摘要: 目的：观察黛柏湿疹膏联合封包疗法治疗慢性湿疹脾虚血燥证的临床疗效。方法：对36例慢性湿疹脾虚血燥证患者采用自身左右对照的方法，将双侧患部分为治疗侧组和对照侧组，分别予黛柏湿疹膏联合封包疗法和糠酸莫米松乳膏外涂治疗4周，观察两组患者治疗前、治疗2周及治疗第4周的皮损程度、受累面积及瘙痒程度，根据EASI湿疹评分判定疗效。并对痊愈、显效及有效的患者，在治疗结束1个月后进行随访。同时记录两组不良反应。结果：共计5例病例脱落。治疗侧组总有效率为90.3%；对照侧组总有效率为67.7%。两组临床总有效率比较差异具有统计学意义(P < 0.05)。治疗侧组皮肤受累面积、皮损严重程度及其各分项，改善均优于对照侧组，具有统计学差异(P < 0.05)。两组瘙痒程度比较，组间比较不具有统计学差异(P > 0.05)。治疗侧组患者加重率为14.3%，对照侧组患者疗后加重率33.3%，组间比较不具有统计学差异(P > 0.05)。两组患者治疗期间均无明显不良反应。结论：外用黛柏湿疹膏联合封包疗法治疗慢性湿疹脾虚血燥证优于糠酸莫米松乳膏外涂，且安全性较好。

Abstract: Objective: To observe the clinical efficacy of Daibai eczema ointment combined with packet ther-apy on chronic eczema complicated with spleen deficiency and blood dryness syndrome. Methods: 36 patients with chronic eczema complicated with spleen deficiency and blood dryness syndrome were compared by self-left and right contrast method. The patients with bilateral lesions were divided into treatment group and control group, who were treated with Daibai eczema cream combined with packet therapy and mometasone furoate cream for 4 weeks, respectively. The degree of skin lesions, affected areas and itching degree were observed before treatment, 2 weeks and 4 weeks after treatment, and the efficacy was judged according to EASI eczema score. The patients who were cured, markedly effective and effective were followed up 1 month after the end of treatment. Adverse reactions in the two groups were recorded at the same time. Results: A total of 5 cases dropped out. The total effective rate in the treatment side group was 90.3%. The total effective rate in the control side group was 67.7%. There was significant difference in clinical total effective rate between the two groups (P < 0.05). The area of skin involvement, the severity of skin lesions and their sub-items and improvement in the treatment side group were better than those in the control side group, with statistical difference (P < 0.05). There was no statistical difference in the degree of pruritus between the two groups (P > 0.05). The aggravation rate was 14.3% in the treatment side group and 33.3% in the control side group. There was no statistical difference between the two groups (P > 0.05). There were no obvious adverse reactions in the two groups during treatment. Conclusion: External application of Daibai eczema ointment combined with packet therapy is superior to external application of mometasone furoate cream in the treatment of chronic eczema complicated with spleen deficiency and blood dryness syndrome, with better safety.